Selected Stock Price Target News — July 17, 2026

Netflix set Q3 revenue guidance below analyst consensus Thursday night. Intuitive Surgical beat its Q2 earnings estimates but disclosed a 1% gross margin headwind from tariffs in the second half of 2026. AGNC Investment received two pre-earnings downgrades before it reports Q2 results this Sunday. More than fifteen analyst desks moved price targets or ratings on these three names Friday morning.

Netflix’s Q3 Revenue Guidance Misses Consensus and Drives Price Target Resets

Q2 Results and the Q3 Shortfall

Netflix provides on-demand streaming of video and games to subscribers in more than 190 countries. Revenue comes from subscriptions and from ads on its lower-priced tier. At the end of Q2, Netflix reported 325 million paying subscribers worldwide. Q2 2026 revenue was $12.56 billion, up 13% year over year. Earnings per share came in at $0.80 versus the $0.79 estimate. Operating margin was 33%. Also, the company narrowed its full-year revenue guidance to $51.0 to $51.4 billion. That range leaves $400 million between the low and high ends.

But Q3 guidance drove Friday’s moves. Netflix projected $12.86 billion in Q3 revenue. Consensus was $13 billion. That gap, roughly 1.1%, triggered more than fifteen price target adjustments Friday morning. Ad revenue growth and membership gains were both cited as Q2 contributors on the earnings call. Even so, the Q3 shortfall relative to analyst models dominated the reaction.

How Desks Responded to the Miss

Guggenheim‘s Michael Morris cut his NFLX target from $120 to $75. That puts him at the low end of the Street after Friday’s reset. Morris carries a 60.88% price target met ratio across 698 calls on 36 stocks, per AnaChart. Still, his $120 target had already sat below several peers before the earnings call.

Evercore ISI‘s Mark Mahaney cut from $115 to $100 and kept Outperform. John Hodulik at UBS trimmed from $130 to $115 and maintained Buy. Citizens‘ Matthew Condon titled his note “Below Consensus Guidance” and held Market Perform. Canaccord’s Maria Ripps reiterated Buy at $125. Of the targets that reset Friday, Mahaney’s $100 comes in second lowest, ahead of only Morris’s $75. In all, no analyst changed their rating Friday. Active targets after the adjustments run from $75 to $125. All active targets sit at some form of Buy-equivalent or Neutral.

Intuitive Surgical’s Tariff Warning Drives PT Cuts Despite an Earnings Beat

Q2 Numbers and the Tariff Disclosure

Intuitive Surgical makes the da Vinci surgical system. Hospitals pay a capital cost for the platform and then recurring fees for instruments, accessories, and service contracts. In Q2, instruments and accessories revenue was $1.73 billion, up 18% year over year. Systems revenue was $685 million. Services revenue was $472 million. Total Q2 revenue was $2.89 billion, up 19% year over year. Non-GAAP EPS came in at $2.80 versus the $2.41 estimate. Systems placed in Q2 rose to 468 from 395 in Q2 2025. Worldwide procedure volume grew 16% year over year.

Still, Intuitive guided full-year gross margins of 68% to 69%, reflecting a 1% headwind from tariffs in the second half. Procedure volume guidance holds at 13.5% to 15.5% growth. Management cited tariff costs on instrument components as the driver of the second-half margin compression. Eight or more analyst desks updated their ISRG price targets Friday morning in response.

Analyst Moves After Earnings

Stifel’s Rick Wise cut his ISRG target from $670 to $550 and maintained Buy. Wise carries a 63.46% price target met ratio across 837 calls on 32 stocks, per AnaChart. His coverage is concentrated in healthcare device names. At $550, his target implies roughly 51% upside, per AnaChart’s upside calculation.

Evercore ISI’s Vijay Kumar reduced his target from $430 to $375 and kept In-Line. Citigroup‘s Joanne Wuensch cut from $590 to $500. Meanwhile, RBC Capital’s Shagun Singh trimmed from $600 to $575 and held Outperform. Bernstein’s Lee Hambright held at $685, the highest of the targets that moved Friday. Yet no desk changed its rating alongside the price target reductions.

AGNC Investment Draws Two Downgrades to Neutral Before Sunday’s Q2 Earnings

What AGNC Does and Where It Stands

AGNC Investment is an agency mortgage REIT. It buys agency MBS backed by Fannie Mae, Freddie Mac, and Ginnie Mae. With those guarantees, the bonds carry no credit risk. Income comes from the spread between bond yields and AGNC’s borrowing cost. The portfolio runs at 7.4x tangible book value leverage. So rate moves amplify their effect on net asset value.

GAAP EPS was negative $0.17 per share in Q1 2026, as portfolio mark-to-market losses offset operating income. Q1 2026 revenue from net interest income was $319 million, up from $159 million in Q1 2025. Net spread and dollar roll income was $0.42 per share for the quarter, above the consensus estimate. That figure exceeded the $0.36 in dividends paid during Q1, or $0.12 per month. Tangible book value per share was $8.38 at March 31, 2026, down 5.6% from $8.88 at year-end 2025. The same monthly dividend rate held into July.

Two Downgrades Before Q2 Earnings

Compass Point‘s Merrill Ross downgraded AGNC from Buy to Neutral and cut her target from $12.50 to $11.50. Ross carries a 50.51% price target met ratio across 271 calls on 35 stocks, per AnaChart. Her coverage spans Financial Services and Industrials names.

JPMorgan‘s Richard Shane downgraded from Overweight to Neutral. Shane carries a 63.81% met ratio across 1,359 calls on 41 stocks, per AnaChart. Both downgrades arrived before any Q2 data, with earnings due Sunday, July 20. AGNC typically discloses tangible book value and net spread income in each quarterly release.

Q2 earnings will provide the first book value update since the Q1 decline. Net spread income in Q2 will show whether the $0.12 monthly dividend rate remains covered by operating income.

The analyst price target data behind today’s moves is drawn from AnaChart’s database of 661,383 price targets and 759,654 ratings across 7,191 analysts and 9,686 tickers going back to 2008. For more on Wall Street’s price target history, see the analyst price target dataset.